BTG Makes Two Buys To Build Interventional Medicine Business
This article was originally published in The Pink Sheet Daily
Executive Summary
BTG of Britain plans two new acquisitions, including a therapy for liver cancer that uses radioactive glass beads and a treatment for dissolving severe blood clots. The deals create an interventional medicine business with potential sales of $1 billion; BTG is funding much of the exercise through a share placement.
You may also be interested in...
BTG Shoots For $1 Billion With Focus On Interventional Medicine
The specialist-focused health care company is building a multi-asset interventional medicines business, including multiple drug-device combination products, which it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
BTG Shoots For $1 Billion Revenue Stars In On-Going Transformation
The specialist health care company is building a multi-asset interventional medicines business that it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
Device/Diagnostics Quarterly Deal Statistics, Q2 2013
Similar to Q1’s deal dollars and volume, device companies raised $1.06 billion through 45 transactions; Bayer HealthCare’s $1 billion purchase of Conceptus was the only device M&A in Q2 to exceed the billion-dollar mark. Diagnostics players raised a total of $2.9 billion during the second quarter, a huge increase over Q1 due to Thermo Fisher Scientific’s $2.46 billion follow-on offering to support its $15.2 billion April acquisition of Life Technology, another Q2 outlier in the M&A category.